Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab
J Clin Oncol
.
2019 May 10;37(14):1151-1153.
doi: 10.1200/JCO.19.00419.
Epub 2019 Mar 22.
Author
Paul M Barr
1
Affiliation
1
1 University of Rochester, Rochester, NY.
PMID:
30901301
DOI:
10.1200/JCO.19.00419
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Lenalidomide
Lymphoma, Mantle-Cell*
Lymphoma, Non-Hodgkin*
Rituximab
Substances
Rituximab
Lenalidomide